-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
Approximately 50% of asthma patients have allergic asthma, which is characterized by increased levels of the cytokines IL-4, IL-5, and IL-13
.
Dupilumab is an IL-4 receptor alpha antagonist that blocks the co-receptor components of IL-4 and IL-13
Approximately 50% of asthma patients have allergic asthma, which is characterized by increased levels of the cytokines IL-4, IL-5, and IL-13
A research letter published in the journal Eur Respir J explored whether the efficacy of dupilumab in the treatment of type 2 hyperphenotypic asthma (blood eosinophils ⩾150 cells/µL or FeNO⩾20 ppb) is affected by the patient’s baseline characteristics (sex, region, Body mass index, age, age at the onset of asthma, drug use, FEV1 before bronchodilator use, study the effects of the number of acute exacerbations of asthma in the previous year, smoking history, blood eosinophil level, FeNO)
544 patients received placebo and 1040 patients received dupilumab
.
The results showed that dupilumab reduced the annual incidence of acute exacerbations of asthma, regardless of demographics or disease characteristics at baseline
544 patients received placebo and 1040 patients received dupilumab
Post-hoc analysis showed that in all demographic and disease characteristics subgroups , dupilumab improved FEV1 before bronchodilator use after 12 weeks of treatment
The results of the study show that dupilumab can reduce the acute exacerbation of type 2 hyperphenotypic asthma and improve FEV1 before bronchiectasis
.
Demographics or disease characteristics do not affect the efficacy of dupilumab in patients with moderate to severe type 2 asthma
The results of the study show that dupilumab can reduce the acute exacerbation of type 2 hyperphenotypic asthma and improve FEV1 before bronchiectasis
Busse WW, Paggiaro P, Muñoz X, et al.
Impact of baseline patient characteristics on dupilumab efficacy in type 2 asthmaLeave a message here
